Resonance Health Limited

Equities

RHT

AU000000RHT2

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 08:06:49 2024-04-25 pm EDT			5-day change	1st Jan Change
0.085 ^AUD	0.00%		+4.94%	+41.67%

Apr. 02	Resonance Health to Acquire Clinical Research Company	MT
Apr. 02	Resonance Health Limited entered into Share Sale Agreement to acquire TrialsWest Pty Ltd from Helen Pavitt, Michelle Davies, and Peter Bremner for AUD 8 million.	CI

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

September 01, 2023 at 01:02 am EDT

Resonance Health Limited announced that Ms Liesl Ellies has resigned as joint Company Secretary, effective 31 August 2023. Mr. Mitchell Wells continues to serve as Company Secretary of Resonance in addition to serving as a Non- executive Director of the Company.

Latest news about Resonance Health Limited

Resonance Health to Acquire Clinical Research Company	Apr. 02	MT
Resonance Health Limited entered into Share Sale Agreement to acquire TrialsWest Pty Ltd from Helen Pavitt, Michelle Davies, and Peter Bremner for AUD 8 million.	Apr. 01	CI
Resonance Health Halts Trading Ahead of 'Material Acquisition' Announcement	Mar. 28	MT
Resonance Health Signs Collaboration Deal for Expansion Into Japanese Market	Mar. 27	MT
Resonance Health Changes Shareholder Registry Services Provider	Mar. 06	MT
Resonance Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Resonance Health Discloses 4.3% Reduction of Issued Shares	Jan. 17	MT
Resonance Health Appoints CFO	23-09-05	MT
Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023	23-09-04	CI
Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary	23-09-01	CI
Resonance Health Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Resonance Health Secures Services Deal for Australian Clinical Trial	23-08-18	MT
Resonance Health Limited Announces Resignation of Nick Allan as Chief Financial Officer	23-07-30	CI
Resonance Health Limited Announces Resignation of Nick Allan as COO and Joint Company Secretary	23-07-30	CI
Resonance Health Gets FDA Clearance to Market HepaFatSmart in US	23-06-29	MT
Resonance Health Appoints CEO	23-06-22	MT
Resonance Health Limited Announces CEO Changes	23-06-22	CI
Resonance Health Ltd Appoints Aaron Brinkworth as Non-Executive Director	23-03-27	CI
Resonance Health Limited Reports Earnings Results for the Half Year Ended December 30, 2022	23-02-28	CI
Resonance Health Files Patent for Liver Fibrosis Detection	22-12-21	MT
Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ	22-12-20	CI
Australian Shares Rally to More than Five-Month High as US Inflation Cools	22-11-11	MT
Resonance Health Secures Two Services Contracts for Liver Iron Measuring Devices; Shares Jump 8%	22-11-10	MT
Resonance Health Limited Announces Contracted for Two New Clinical Trials	22-11-10	CI
Resonance Health Introduces Resonance Clinical	22-10-25	MT

Chart Resonance Health Limited

Duration

Period

More charts

Company Profile

Resonance Health Limited is an Australia-based MedTech company. The Company specializes in the development and delivery of non-invasive medical imaging software and services. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESONANCE HEALTH LIMITED	+41.67%	24.77M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology